Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF OPERATING OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 16,307 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,477 · Balance 14,506 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,611 · Balance 16,117 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,740 · Balance 17,857 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,457 · Balance 20,314 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,007 · Balance 16,307 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,250 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 9,250 · Balance 9,250 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,371 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 2,457 · Balance 7,371 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,481 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,740 · Balance 3,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,611 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,611 · Balance 1,611 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,477 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 36,950 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 36,950 · Balance 36,950 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 23,234 | $28.02 | $651,016.68 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 10 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,415 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.11. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,157 | $17.76 | $20,548.32 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,671 | $11.10 | $96,248.10 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 13,406 | $13.35 | $178,970.10 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 8,303 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,303 Underlying: Class A Ordinary Share · 8,303 shares Expires 2035-04-30 F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F9 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 8,043 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,043 Underlying: Class A Ordinary Share · 8,043 shares Expires 2035-04-30 F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F8 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 5,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,225 Underlying: Class A Ordinary Share · 5,225 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F7 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F7 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 4,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,976 Underlying: Class A Ordinary Share · 4,976 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F6 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. F6 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 15,307 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 15 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,361 Underlying: Class A Ordinary Share · 15,307 shares Expires 2033-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F7 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 7,432 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 14 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,252 Underlying: Class A Ordinary Share · 7,432 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F6 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,296 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 13 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,658 Underlying: Class A Ordinary Share · 6,296 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 20,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 12 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 20,000 shares Expires 2030-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 15,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 11 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 15,000 shares Expires 2030-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 64,035 | $25.21 | $1,614,322.35 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,415 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $25.00 and $25.45. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 15,307 | $10.76 | $164,703.32 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 7,432 | $11.97 | $88,961.04 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,296 | $12.97 | $81,659.12 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 20,000 | $15.50 | $310,000.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 15,000 | $15.52 | $232,800.00 |
DisclosureSEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 18,259 | $20.29 | $370,475.11 |
DisclosureSEC source: 0001415889-25-011209 · form4-04232025_080423.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,415 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.05 and 20.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010478 · form4-04092025_080436.xml · derivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,477 Underlying: Class A Ordinary Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 727 | $20.28 | $14,743.56 |
DisclosureSEC source: 0001415889-25-010478 · form4-04092025_080436.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,674 Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010478 · form4-04092025_080436.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · derivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,221 Underlying: Class A Ordinary Share · 1,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · derivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,222 Underlying: Class A Ordinary Share · 1,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 19,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · derivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,657 Underlying: Class A Ordinary Share · 19,657 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,828 Underlying: Class A Ordinary Share · 9,828 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 39,364 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · derivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,364 Underlying: Class A Ordinary Share · 39,364 shares Expires 2035-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 511 | $21.77 | $11,124.47 |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,924 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 473 | $21.77 | $10,297.21 |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,435 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010012 · form4-04032025_090416.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008620 · form4-03192025_090322.xml · derivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 292 | $22.61 | $6,602.12 |
DisclosureSEC source: 0001415889-25-008620 · form4-03192025_090322.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,556 Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-008620 · form4-03192025_090322.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| January 15, 2025 Filed Mar 19, 2025 21:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 1,118 | $16.00 | $17,888.00 |
DisclosureSEC source: 0001415889-25-008620 · form4-03192025_090322.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,854 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2024 to January 15, 2025. The acquisition of such shares was exempt pursuant to Rule 16b-3(e). Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 24,776 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 18 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,924 Underlying: Class A Ordinary Share · 24,776 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 F13 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 29,730 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 17 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,534 Underlying: Class A Ordinary Share · 29,730 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 F12 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 14,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 16 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 14,000 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 F11 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 1,160 | $27.12 | $31,459.20 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 10 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,736 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $26.995 to $27.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 67,346 | $26.10 | $1,757,730.60 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,896 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.88 to $26.80. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 24,776 | $11.97 | $296,568.72 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 29,730 | $11.10 | $330,003.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 14,000 | $8.83 | $123,620.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 3, 2024 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 15 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 994 Underlying: Class A Ordinary Share · 994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F10 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. F10 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 345 | $26.74 | $9,225.30 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,736 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 14 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,833 Underlying: Class A Ordinary Share · 1,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 13 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,954 Underlying: Class A Ordinary Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,100 | $0.00 Strike: $26.74 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 12 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,100 Underlying: Class A Ordinary Share · 36,100 shares Expires 2034-08-31 F7 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.